Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prajna Guha

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Cancer Gene Therapy|June 4, 2019
HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA<sup>+</sup> liver metastasesSteven C Katz, John Hardaway, Ethan Prince, et al.
Cancer Gene Therapy|June 13, 2022
Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibitionChandra C Ghosh, Kara R Heatherton, Kyle P O' Connell, et al.
Frontiers in Oncology|October 22, 2025
Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor modelsLauren Cournoyer, Yujia Liu, David B Jaroch, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2015
Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-TRachel A Burga, Mitchell Thorn, Gary R Point, et al.
Vaccines|August 28, 2021
Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor ActivityLouis F Chai, John C Hardaway, Kara R Heatherton, et al.
The Journal of Clinical Investigation|February 23, 2011
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutationTalita M Marin, Kimberly Keith, Benjamin Davies, et al.
The Journal of Surgical Research|December 20, 2021
Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis ModelLouis F Chai, John C Hardaway, Kara R Heatherton, et al.
Journal for Immunotherapy of Cancer|August 27, 2020
HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug deliverySteven C Katz, Ashley E Moody, Prajna Guha, et al.
Journal for Immunotherapy of Cancer|July 22, 2024
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastasesChandra C Ghosh, Lauren Cournoyer, Yujia Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 18, 2016
Gene control of tyrosine kinase TIE2 and vascular manifestations of infectionsChandra C Ghosh, Sascha David, Ruyang Zhang, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Cancer Gene Therapy|June 4, 2019
HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA<sup>+</sup> liver metastasesSteven C Katz, John Hardaway, Ethan Prince, et al.
Cancer Gene Therapy|June 13, 2022
Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibitionChandra C Ghosh, Kara R Heatherton, Kyle P O' Connell, et al.
Frontiers in Oncology|October 22, 2025
Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor modelsLauren Cournoyer, Yujia Liu, David B Jaroch, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2015
Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-TRachel A Burga, Mitchell Thorn, Gary R Point, et al.
Vaccines|August 28, 2021
Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor ActivityLouis F Chai, John C Hardaway, Kara R Heatherton, et al.
The Journal of Clinical Investigation|February 23, 2011
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutationTalita M Marin, Kimberly Keith, Benjamin Davies, et al.
The Journal of Surgical Research|December 20, 2021
Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis ModelLouis F Chai, John C Hardaway, Kara R Heatherton, et al.
Journal for Immunotherapy of Cancer|August 27, 2020
HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug deliverySteven C Katz, Ashley E Moody, Prajna Guha, et al.
Journal for Immunotherapy of Cancer|July 22, 2024
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastasesChandra C Ghosh, Lauren Cournoyer, Yujia Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 18, 2016
Gene control of tyrosine kinase TIE2 and vascular manifestations of infectionsChandra C Ghosh, Sascha David, Ruyang Zhang, et al.
Pageof 3